Sunresin’s new facility, with a total investment of approximately USD 160 million, will cover 18 hectares and significantly increase the production capacity of chromatography resins and advanced separation materials, thereby reinforcing the company’s long-term commitment to the life sciences sector.

Sunresin New Materials Co., Ltd. has announced plans to invest USD 160 million in the construction of a High-End Life Science Advanced Materials Industrial Park in the Pucheng High-Tech Industrial Development Zone, China.

The project will span approximately 18 hectares and serve as a flagship facility for the development and large-scale production of critical bioprocessing materials, including:

· Agarose and polymeric chromatography media

· Enzyme carriers

· Resins for oligonucleotide and peptide solid phase synthesis

· Adsorption resins and separation materials

· GMP facility for manufacturing APIs and excipients

· Resins for ultrapure water production

· Food- and biopharma-grade resins

· Chromatographic equipment

This investment highlights Sunresin’s strategy to grow its life sciences business, meet the increasing global demand for downstream processing solutions, and solidify its standing as a leading innovator in the field.

“The creation of this new industrial park reflects Sunresin's confidence in the long-term growth of the life sciences sector,” said Dr. Ivy Gao, CEO of Sunresin. “By expanding our capacity and capabilities, including a new GMP facility for the manufacturing of APIs and excipients, we aim to provide the global biopharmaceutical industry with more reliable, high-performance chromatography resins and separation technologies.”

Although the initiative may not affect financial performance immediately, it positions Sunresin to take advantage of emerging opportunities in biopharmaceuticals, advanced therapies, and global downstream processing. According to the company, land acquisition will take place through a public auction, and construction and development are subject to the usual regulatory approvals.